GNE-4997 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of the PI3K/AKT/mTOR signaling pathway, which is often dysregulated in various cancers. By targeting this pathway, GNE-4997 aims to inhibit tumor growth and proliferation, making it a promising candidate for cancer treatment. Its application is currently focused on preclinical studies to evaluate its efficacy, safety, and potential use in combination therapies for cancers such as breast, prostate, and hematologic malignancies. Additionally, researchers are exploring its role in overcoming resistance to existing therapies, particularly in cases where traditional treatments have failed.